Eli Lilly reports that adding eloralintide, an experimental once weekly amylin drug, to tirzepatide produced average weight loss of up to 23.3% at 48 weeks in adults with obesity or overweight and type 2 diabetes, against 14.8% for tirzepatide 15 mg alone. The phase 2b results were presented on 30 September at the European Association for the Study of Diabetes meeting in Milan and have not been published in a peer reviewed journal.
Tirzepatide, sold as Mounjaro and Zepbound, activates the GIP and GLP-1 receptors. Eloralintide works by a different route, as a selective agonist of amylin receptors. The combination is called EloraTZP, and in this trial the two drugs were given as separate pen injections.
How the trial worked
The 48 week, double blind, placebo controlled trial (NCT06603571) randomised 367 adults in the United States and Argentina across ten treatment groups: placebo, eloralintide alone, tirzepatide 15 mg alone, and four eloralintide and tirzepatide combinations. Participants started at an average of 105.4 kg with an HbA1c of 8.1%. Lilly's figures use the efficacy estimand, which estimates the effect while people are taking treatment.
What the results show
At 48 weeks the four combinations lost an average of 13.2% (eloralintide 3 mg with tirzepatide 5 mg), 19.4% (6 mg with 5 mg), 19.9% (6 mg with 10 mg) and 23.3% (9 mg with 15 mg), which is 24.6 kg at the top dose. Tirzepatide 15 mg alone lost 14.8%, eloralintide alone lost 8.2% to 12.3%, and placebo lost 3.0%.
HbA1c, a measure of blood sugar control, fell by 2.2 to 2.9 percentage points with the combinations, against 2.4 with tirzepatide alone and 0.3 with placebo. Between 45% and 77% of people in the combination groups reached an HbA1c below 5.7%, against 10.9% on placebo.
Side effects were mainly gastrointestinal, mostly during dose escalation, and more common with the combinations than with either drug alone. Across all groups 11.4% stopped treatment because of side effects, and nausea affected 25.9% of participants, diarrhoea 24.3% and constipation 21.0%. Lilly's release gives the rate of stopping because of side effects as 10.8% to 27.0% in the combination groups, 0% to 10.8% with eloralintide alone, 2.9% with tirzepatide alone and 16.7% with placebo, a placebo figure Medical Daily calls unusually high and says complicates comparison.
What is still unknown
The figures come from a conference presentation and a press summary, not a paper. Because the efficacy estimand assumes people kept taking treatment, results in practice could be smaller, and the share of people completing treatment ranged from 59.5% to 92.1% across groups. Everyone in the trial had type 2 diabetes, so the results may not carry over to people without it, and no trial has compared the combination with retatrutide or any other triple agonist.
Lilly says it plans to advance an EloraTZP co-formulation product, which Medical Daily describes as a single injection, into phase 3 by the end of 2026. Eloralintide alone produced up to about 20% weight loss at 48 weeks in 263 people without diabetes in a phase 2 trial published in The Lancet in 2025. The trial was funded by Lilly, and lead author Liana Billings reports consulting fees and research funding from several companies, Lilly among them.